Oculis, an ophthalmic biopharmaceutical company, has over-completed Series C financing, and Baiao Wealth and Huiding Investment jointly led the investment

Oculis announced that it has over-completed its Series C financing
.

Oculis is a biopharmaceutical company focused on the clinical stage, which improves the vision and living standards of patients through the development of new ophthalmic treatments

This round of financing aims to promote shareholder value and bring innovative ophthalmic drugs to patients
.

With the help of this round of financing, Oculis will be able to accelerate the development of topical drug preparations for retinal and anterior ocular diseases, and achieve key short-term goals, including: promoting the development of Oculis's innovative series of topical ophthalmic drugs in the clinical phase; To meet the needs of ophthalmology treatment, Oculis continues to expand the candidate drug products of innovative ophthalmic preparations by virtue of its advantages such as its patented formulation platform; develop Oculis's international strategy, with the mission of improving the vision and life of patients around the world, and actively research and develop pioneering ophthalmology Treatment solutions have become a strong participant in the global ophthalmic pharmaceutical market

After the completion of this round of financing, Baiao Wealth Management Partner Huang Yifei and Huiding Investment Management Partner Dr.